Stocks to Watch: Penguin Solutions, Esperion Therapeutics

Dow Jones

10/08

By Kelly Cloonan

Penguin Solutions expects sales growth to slow in the current fiscal year after it swung to a profit in its latest quarter. The artificial intelligence company forecast sales growth of about 6%, plus or minus 10%, for fiscal 2026, compared to 17% growth in the year that ended Aug. 29. Chief Executive Mark Adams said the company is seeing momentum in its core businesses. Shares fell 13% to $23.60 in after-hours trading.

Esperion Therapeutics commenced an underwritten public offering of its common stock. All shares in the proposed offering will be sold by Esperion. In April, the biopharmaceutical company filed for a $400 million mixed shelf offering with the Securities and Exchange Commission. Shares slid 18% to $2.54 after market close.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

October 07, 2025 19:04 ET (23:04 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2573994973"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573994973\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573994973?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-08 07:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573994973","market":"fut","top_or_hot":-1,"title":"Stocks to Watch: Penguin Solutions, Esperion Therapeutics","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Penguin Solutions expects sales growth to slow in the current fiscal year after it swung to a profit in its latest quarter. The artificial intelligence company forecast sales growth of about 6%, plus or minus 10%, for fiscal 2026, compared to 17% growth in the year that ended Aug. 29. Chief Executive Mark Adams said the company is seeing momentum in its core businesses. Shares fell 13% to $23.60 in after-hours trading. \n</p>\n<p>\n  Esperion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> commenced an underwritten public offering of its common stock. All shares in the proposed offering will be sold by Esperion. In April, the biopharmaceutical company filed for a $400 million mixed shelf offering with the Securities and Exchange Commission. Shares slid 18% to $2.54 after market close. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n   Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 07, 2025 19:04 ET (23:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks to Watch: Penguin Solutions, Esperion Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks to Watch: Penguin Solutions, Esperion Therapeutics\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-10-08 07:04</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Penguin Solutions expects sales growth to slow in the current fiscal year after it swung to a profit in its latest quarter. The artificial intelligence company forecast sales growth of about 6%, plus or minus 10%, for fiscal 2026, compared to 17% growth in the year that ended Aug. 29. Chief Executive Mark Adams said the company is seeing momentum in its core businesses. Shares fell 13% to $23.60 in after-hours trading. \n</p>\n<p>\n  Esperion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> commenced an underwritten public offering of its common stock. All shares in the proposed offering will be sold by Esperion. In April, the biopharmaceutical company filed for a $400 million mixed shelf offering with the Securities and Exchange Commission. Shares slid 18% to $2.54 after market close. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n   Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 07, 2025 19:04 ET (23:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2573994973","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573994973","pubTimestamp":1759878240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Penguin Solutions expects sales growth to slow in the current fiscal year after it swung to a profit in its latest quarter. The artificial intelligence company forecast sales growth of about 6%, plus or minus 10%, for fiscal 2026, compared to 17% growth in the year that ended Aug. 29. Chief Executive Mark Adams said the company is seeing momentum in its core businesses. Shares fell 13% to $23.60 in after-hours trading.Esperion Therapeutics commenced an underwritten public offering of its common stock. All shares in the proposed offering will be sold by Esperion. In April, the biopharmaceutical company filed for a $400 million mixed shelf offering with the Securities and Exchange Commission. Shares slid 18% to $2.54 after market close.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ESPR":"Esperion Therapeutics Inc."},"translate_title":"值得关注的股票：Penguin Solutions、Esperion Therapeutics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESPR":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Penguin Solutions expects sales growth to slow in the current fiscal year after it swung to a profit in its latest quarter. The artificial intelligence company forecast sales growth of about 6%, plus or minus 10%, for fiscal 2026, compared to 17% growth in the year that ended Aug. 29. Chief Executive Mark Adams said the company is seeing momentum in its core businesses. Shares fell 13% to $23.60 in after-hours trading. \n\n\n  Esperion Therapeutics commenced an underwritten public offering of its common stock. All shares in the proposed offering will be sold by Esperion. In April, the biopharmaceutical company filed for a $400 million mixed shelf offering with the Securities and Exchange Commission. Shares slid 18% to $2.54 after market close. \n\n\n \n\n\n   Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n  (END) Dow Jones Newswires\n\n\n  October 07, 2025 19:04 ET (23:04 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}